HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Webster, W.B. Articles by Morrissey, M. A. Search for Related Content PubMed PubMed Citation Articles by Webster, W.B. Articles by Morrissey, M. A.

Pharmacokinetics of Indium-111-Labeled B72.3 Monoclonal Antibody in Colorectal Cancer Patients

The Departments of Pharmacy and Nuclear Medicine, Bay Pines VA Medical Center, Bay Pines, Florida
Colleges of Pharmacy, University of Florida, Gainesville, Florida
Southeastern University, Miami, Florida
College of Medicine, University of South Florida, Tampa, Florida

Correspondence: For reprints contact: W. Webster, Pharm D, P.O. Box 485, Bay Pines, FL 33504-0485.

ABSTRACT

Mean time parameters provide a new approach to plasma pharmacokinetics of radiolabeled Mabs that may show important patient differences affecting diagnosis or treatment. We determined mean time pharmacokinetic parameters for 11 patients entered in a Phase I/II clinical trial for detection of colorectal cancer. Patients were administered 0.5–2 mg of B72.3 anti-TAG-72 radiolabeled with 3.5–5 mCi of ¹¹¹In, plasma activity was measured over time. Mean time pharmacokinetic parameters were ( ± s.e.m.): mean residence time; body (MRT_B) 88.9 ± 7.2 hr, central (MAT_C) 73.8 ± 6.0 hr; mean transit time, central (MTT_C) 41.1 ± 9.0 hr; mean residence time, periphery (MRT_P) 15.1 ± 3.4 hr; intrinsic mean residence time, periphery (IMPT_P) 390 ± 7.6 hr; mean transit time, periphery (MTT_P) 24.0 ± 6.7 hr; probability of distribution (PRD) 50% ± 10%; and compartmental cycles of 4.54 ± 2.3 times. In patients with increased circulating specific TAG-72 antigen, MRT_C > MTT_C and å 1. In patients without specific antigen, MRT_C MTT_C and « 1. Pharmacokinetic studies may identify patients who do not have the tumor produced target antigen for the specific Mab and may provide an opportunity to select another specific Mab with an increased chance for successful diagnosis or treatment.